Quick Answer
ZyVersa Therapeutics, Inc. reported Shares Outstanding of 8.10 million shares for fiscal year 2025.
ZyVersa Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 8.10M | +222.8% |
| 2024 | 2.51M | +523.6% |
| 2023 | 402,205 | +56.1% |
| 2022 | 257,604 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 8.10M | +653.7% | +66.1% |
| June 30, 2025 | 4.87M | +483.7% | +89.8% |
| March 31, 2025 | 2.57M | +207.6% | +2.4% |
| December 31, 2024 | 2.51M | +523.6% | +133.5% |
| September 30, 2024 | 1.07M | -97.5% | +28.7% |
| June 30, 2024 | 834,896 | -96.5% | +0.0% |
| March 31, 2024 | 834,896 | -90.9% | +107.6% |
| December 31, 2023 | 402,205 | -95.5% | -99.1% |
- ZyVersa Therapeutics, Inc. showed an increase of +222.8% in Shares Outstanding compared to the prior fiscal year.
- Over the 2022–2025 period, ZyVersa Therapeutics, Inc.’s shares outstanding has grown by 3042.8% (from 257.6 thousand shares to 8.10 million shares).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: